Recent Company News

• 08:36 AM ET Aug 22, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:37 PM ET Aug 25, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 03:09 AM ET Aug 25, 2025
  

  Daiichi Sankyo's ENHERTU obtains Japan MHLW approval as first HER2 direct medicine for treatment of breast cancer (¥3716.0000, 0)

• 08:52 PM ET Aug 22, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 01:31 PM ET Aug 22, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 24-Aug

• 07:57 AM ET Aug 22, 2025
  

  Daiichi Sankyo (4568.JP) and AstraZeneca announce China NMPA approval of Dazhuoyou (Datroway) in HR-positive, HER2-negative metastatic breast cancer (12052.0000p, +4)

• 08:07 PM ET Aug 19, 2025
  

  Hutchmed completes patient enrollment for Phase III Trial of ORPATHYS and TAGRISSO as first-line therapy for certain NSCLC patients in China (HK$25.90, 0.00)

• 11:09 PM ET Aug 18, 2025
  

  Singapore approves Beyfortus (nirsevimab) for prevention of RSV in newborns and infants (€85.58, 0.00)